Key result
Statin use is linked to ~40% lower all-cause mortality in adults with Parkinson's disease.
Why the study?
The impact of statin use on progression and survival in Parkinson's disease patients, especially in Asian populations, remains unclear.
Does statin use reduce all-cause mortality in adults with Parkinson's disease?
Cohort (n=3,152)
Does statin use reduce all-cause mortality in adults with Parkinson's disease?
Hazard Ratio: 0.6 (95% CI 0.521–0.691)
Statin use and higher cumulative doses are associated with reduced all-cause mortality in patients with Parkinson's disease.
OBJECTIVE: The impact of statin use on the progression and survival of patients with Parkinson's disease (PD) remains unclear. Moreover, evidence in Asian populations is limited. This study aimed to assess the associations between statin prescription, cumulative dosage, and all-cause mortality in PD patients. METHODS: This retrospective cohort study was conducted using sample data obtained from the Korean National Health Insurance Service (KNHIS) claims database. The study included 3,152 adults who were diagnosed with PD and whose history of statin use and cumulative dose information were obtained from claims records. Data were collected from the KNHIS database, and all eligible participants were followed longitudinally to determine all-cause mortality. The primary outcome was all-cause mortality, and the exposures were statin use (yes or no) and cumulative dose. The analysis was conducted using Cox proportional hazards regression adjusted for relevant covariates. RESULTS: Statin use was associated with a lower risk of all-cause mortality (hazard ratio [HR], 0.600; 95% confidence interval [CI], 0.521-0.691). Among statin users, a higher cumulative statin dose was linked to a further reduction in mortality (HR, 0.800; 95% CI, 0.761-0.842). CONCLUSION: Statin use and increased cumulative exposure were associated with reduced all-cause mortality in patients with PD, and these findings suggest a potential survival benefit and warrant further investigation in diverse populations.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) conducted a cohort in Parkinson's disease (n=3,152). Statin use vs. No statin use was evaluated on All-cause mortality (HR 0.600, 95% CI 0.521-0.691). Statin use was associated with a lower risk of all-cause mortality in adults with Parkinson's disease (HR 0.600; 95% CI 0.521-0.691), with higher cumulative doses linked to further risk reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: